Login / Signup

mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease.

John P GradySarah J PickettYi Shiau NgCharlotte L AlstonEmma L BlakelySteven A HardyCatherine L FeeneyAlexandra A BrightAndrew M SchaeferGráinne S GormanRichard Jq McNallyRobert W TaylorDoug M TurnbullRobert McFarland
Published in: EMBO molecular medicine (2019)
Mitochondrial disease associated with the pathogenic m.3243A>G variant is a common, clinically heterogeneous, neurogenetic disorder. Using multiple linear regression and linear mixed modelling, we evaluated which commonly assayed tissue (blood N = 231, urine N = 235, skeletal muscle N = 77) represents the m.3243A>G mutation load and mitochondrial DNA (mtDNA) copy number most strongly associated with disease burden and progression. m.3243A>G levels are correlated in blood, muscle and urine (R2 = 0.61-0.73). Blood heteroplasmy declines by ~2.3%/year; we have extended previously published methodology to adjust for age. In urine, males have higher mtDNA copy number and ~20% higher m.3243A>G mutation load; we present formulas to adjust for this. Blood is the most highly correlated mutation measure for disease burden and progression in m.3243A>G-harbouring individuals; increasing age and heteroplasmy contribute (R2 = 0.27, P < 0.001). In muscle, heteroplasmy, age and mtDNA copy number explain a higher proportion of variability in disease burden (R2 = 0.40, P < 0.001), although activity level and disease severity are likely to affect copy number. Whilst our data indicate that age-corrected blood m.3243A>G heteroplasmy is the most convenient and reliable measure for routine clinical assessment, additional factors such as mtDNA copy number may also influence disease severity.
Keyphrases
  • mitochondrial dna
  • copy number
  • genome wide
  • skeletal muscle
  • dna methylation
  • oxidative stress
  • risk factors
  • gene expression
  • adipose tissue
  • artificial intelligence